CH5 benzothiazole schiff base protects against DEHP-induced testicular injury via involvement of COX-2-associated inflammatory signaling and spermatogenesis recovery in adult zebrafish.
Abstract
The reproductive system is impacted by the endocrine disrupting chemical di-(2-ethylhexyl) phthalate (DEHP) as a result of oxidative stress, inflammation, and disruption of steroidogenesis. The objective of the current investigation was to assess the therapeutic efficacy of a benzothiazole-based schiff base CH5 derivative in the treatment of DEHP-induced testicular injury. Adult male zebrafish were exposed to DEHP (20 μg/L) treatment for 21 days to cause testicular damage, after which CH5 (50 μM and 75 μM) and clomiphene citrate (positive control) were administered orally for 14 days. The protective effect of CH5 was evaluated using in silico, in vitro, behavioral, sperm quality, reproductive health, biochemical, and mRNA expression. In silico analysis identified the key target proteins, such as esr1, cox-2, egfr, hsp90, and igf1r, while molecular docking has indicated that cox-2 possesses the highest binding affinity to CH5. Also, the derivative exhibited low cytotoxicity, potent antioxidant activity, and minimal embryotoxicity at therapeutic concentrations up to 75 μM. Therapeutic treatment with CH5 (75 μM) significantly improved courtship and mate recognition behavior by increasing female interactions, improving sperm concentration (6.63 × 10⁶ sperm/mL), reducing intracellular ROS in sperm cells, enhancing fertilization and hatching rates. In addition, the activities of SOD, CAT, and GST were enhanced by CH5, while LDH and MPO were diminished. Also, CH5 treatment improves the gonadosomatic index (3.56%), preserved testicular structure, upregulated esr1 expression and downregulated il-1β, tnf-α, inos and cox-2. These results indicate that CH5 demonstrates its prospective promise as a therapeutic candidate against endocrine disruptor-induced male reproductive toxicity.